PURPOSE: The aims of this study were to assess health-related quality of life (HRQoL), depression, adverse physical symptoms, and sexual function within Serbian long-term testicular cancer survivors (TCS) and to address cultural specificity. METHODS: This is a cross-sectional study involving 202 TCS, followed up after platinum-based chemotherapy. The HRQoL was measured using the Short Form 36 and the European Organization for Research and Treatment of Cancer Quality of Life questionnaire. The Beck Depression Inventory (BDI) was used to explore general depressive status while sexual function was assessed using a nine-item questionnaire. RESULTS: The mean follow-up time since treatment was 47.3 ± 26.8 months. The highest values of the SF-36 scales were obtained for physical functioning, and the lowest SF-36 values were obtained for vitality. Age of patients and BDI scores statistically significantly influenced total quality of life. The mean score of the whole sample on the BDI-II was 4.0. Age is the only statistically significant risk factor for the development of depression. A total of 27.3% TCS reported decreased sexual function compared to the period before treatment. Any level of impairment of erectile function was reported by 20.8% patients and problems with ejaculation by 25.7% patients. Loss of desire was reported by 17.3% TCS. The presence of sexual problems statistically significantly lowered scores of SF-36 domains. CONCLUSION: Sexual problems seriously impaired HRQoL in TCS. Additionally, HRQoL was also affected by age, depression, and fatigue. Serbian TCS achieved high levels of SF-36 scores, and these results are comparable to studies conducted in developed countries.
PURPOSE: The aims of this study were to assess health-related quality of life (HRQoL), depression, adverse physical symptoms, and sexual function within Serbian long-term testicular cancer survivors (TCS) and to address cultural specificity. METHODS: This is a cross-sectional study involving 202 TCS, followed up after platinum-based chemotherapy. The HRQoL was measured using the Short Form 36 and the European Organization for Research and Treatment of Cancer Quality of Life questionnaire. The Beck Depression Inventory (BDI) was used to explore general depressive status while sexual function was assessed using a nine-item questionnaire. RESULTS: The mean follow-up time since treatment was 47.3 ± 26.8 months. The highest values of the SF-36 scales were obtained for physical functioning, and the lowest SF-36 values were obtained for vitality. Age of patients and BDI scores statistically significantly influenced total quality of life. The mean score of the whole sample on the BDI-II was 4.0. Age is the only statistically significant risk factor for the development of depression. A total of 27.3% TCS reported decreased sexual function compared to the period before treatment. Any level of impairment of erectile function was reported by 20.8% patients and problems with ejaculation by 25.7% patients. Loss of desire was reported by 17.3% TCS. The presence of sexual problems statistically significantly lowered scores of SF-36 domains. CONCLUSION: Sexual problems seriously impaired HRQoL in TCS. Additionally, HRQoL was also affected by age, depression, and fatigue. Serbian TCS achieved high levels of SF-36 scores, and these results are comparable to studies conducted in developed countries.
Authors: Christopher Kim; Katherine A McGlynn; Ruth McCorkle; Ralph L Erickson; David W Niebuhr; Shuangge Ma; Barry Graubard; Briseis Aschebrook-Kilfoy; Kathryn Hughes Barry; Yawei Zhang Journal: Qual Life Res Date: 2011-04-17 Impact factor: 4.147
Authors: J P van Basten; G Jonker-Pool; M F van Driel; D T Sleijfer; H B van de Wiel; H J Mensink; H Schraffordt-Koops; H J Hoekstra Journal: Br J Urol Date: 1996-11
Authors: Alv A Dahl; Carl Fredrik Haaland; Arnstein Mykletun; Roy Bremnes; Olav Dahl; Olbjørn Klepp; Erik Wist; Sophie D Fosså Journal: J Clin Oncol Date: 2005-04-01 Impact factor: 44.544
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Philip Blach Rossen; Anette Fischer Pedersen; Robert Zachariae; Hans von der Maase Journal: J Clin Oncol Date: 2009-10-26 Impact factor: 44.544
Authors: Shirin ArdeshirRouhaniFard; Paul C Dinh; Patrick O Monahan; Sophie D Fossa; Robert Huddart; Chunkit Fung; Yiqing Song; Darren R Feldman; Robert J Hamilton; David J Vaughn; Neil E Martin; Christian Kollmannsberger; Lawrence Einhorn; Kurt Kroenke; Lois B Travis Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-04-13 Impact factor: 4.254
Authors: Paolo Capogrosso; Luca Boeri; Matteo Ferrari; Eugenio Ventimiglia; Giovanni La Croce; Umberto Capitanio; Alberto Briganti; Rocco Damiano; Francesco Montorsi; Andrea Salonia Journal: Asian J Androl Date: 2016 Jan-Feb Impact factor: 3.285
Authors: Giuseppe Schepisi; Silvia De Padova; Delia De Lisi; Chiara Casadei; Elena Meggiolaro; Federica Ruffilli; Giovanni Rosti; Cristian Lolli; Giorgia Ravaglia; Vincenza Conteduca; Alberto Farolfi; Luigi Grassi; Ugo De Giorgi Journal: Front Endocrinol (Lausanne) Date: 2019-02-25 Impact factor: 5.555